ONWARD Medical Records Sales Increase in the Third Quarter of 2025
ONWARD Medical has announced positive results for the third quarter of 2025, marked by an increase in sales and significant regulatory advancements for its ARC-EX and ARC-IM systems.
Financial Performance and Investor Interest
According to the company's press release, ONWARD Medical achieved a turnover of 1.7 million euros in the third quarter of 2025. In October, the company raised over 50 million euros in capital, strengthening its financial capacity until the first quarter of 2027. The cash balance as of October 31, 2025, stood at 77.7 million euros. The company also noted increased investor interest, with coverage from five banks recommending the purchase of its shares.
Regulatory Progress and Commercial Achievements
ONWARD Medical sold 40 ARC-EX systems during the quarter, thus meeting its commercial targets. In terms of regulation, the company obtained FDA authorization for a global study on ARC-IM and received CE certification for ARC-EX, paving the way for its marketing in Europe for clinical and home use. The company also announced scientific publications in prestigious journals, reinforcing the clinical validation of its technologies.
Future Prospects and Market Expansion
The company is preparing to launch its Empower BP study before the end of the year, aimed at evaluating ARC-IM for managing blood pressure instability in individuals with spinal cord injuries. The American market is expanding with the authorization of home use for ARC-EX. The outlook for 2026 remains positive, supported by the commitment to continue the implants of ARC-IM and ARC-BCI to explore new indications, including improving mobility in cases of spinal injuries and Parkinson's disease.
